BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Blogs » BioWorld Perspectives » How to Pitch BioWorld: Five More Tips

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

How to Pitch BioWorld: Five More Tips

Sep. 1, 2011
By Trista Morrison

If you read our post earlier this week (Top 5 Tips for Pitching BioWorld), you know what kind of news BioWorld Today covers. Here are five more helpful hints regarding how to work with us:

  1. How to contact us. Our direct phone numbers are on page two of BioWorld Today or here. Aside from the DC and science beats mentioned in Tip #4, we don’t specialize, so you can reach out to any of us. If you know your news is not cover-worthy (i.e. a patent, a personnel appointment, fast track or orphan drug designation, an early stage trial initiation, etc.), send it to newsdesk@bioworld.com. We check the newsdesk email all day, every day. It’s a good idea to cc newsdesk on any pitches in case the reporter you are targeting is out of the office.
  2. When we bite, reel us in. We don’t have a lot of time between when we assign stories at 10 a.m. EST and when they are due at 4:30 p.m. EST. If we contact you (PR firm) looking for an interview, please let us know right away that you got the message and are working on it. Otherwise we might think you’re out of the office and just contact your client directly, and if we can’t reach them, we might kill the story. Along these lines, if you’re going to issue a press release, make sure you have a spokesperson available. If the CEO will be on a plane all day, line up someone else who can talk to media.
  3. A note on going off the record. PR firms generally advise clients that there is no such thing as off the record. I did it when I was in PR, but as a reporter, I can tell you that’s definitely not true. At BioWorld, we depend on industry relationships, and we aren’t going to jeopardize those by printing something said off the record. Off-the-record conversations help us gather background information, and they help you build the relationship and keep us educated about your company. But remember that it’s vital to clarify the status of the discussion up front, not a day later.
  4. More on embargoes. I mentioned embargoes in Tip #3, but I want to mention them again because they are so critical to how BioWorld operates. We always honor embargoes. If you can tell us about your news a few days ahead of time, we can get a jump-start on our background research. Also, since our publication comes out late in the evening, some companies will work with us ahead of time and then let us publish the story the night before their press release crosses the wire, so folks wake up and see the press release and the BioWorld cover story on the same day. Offering us that kind of arrangement always gives your newsworthiness a boost.
  5. About clarifications and corrections. We want to be accurate, so don’t hesitate to ask for a correction if something is factually incorrect. But please don’t ask for a correction because we called your trial results “mixed” instead of “stunningly positive” when you missed three out of four endpoints. (Yes, this has happened).

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 17, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • EU flag vector

    European Commission floats multiple fixes for MDR, IVDR

    BioWorld MedTech
    The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing